Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide (TCM-TMAO)

5. december 2017 opdateret af: Lei Wang, Guangdong Provincial Hospital of Traditional Chinese Medicine

Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide in Acute Coronary Syndromes : A Randomized Placebo Controlled Trial

Recent studies highlight the participation of gut microbes in the pathogenesis of both atherosclerotic heart disease and its adverse thrombotic events. Trimethylamine N-oxide (TMAO) is a plasma metabolite shown to be formed through a metaorganismal pathway involving nutrient precursors abundant in a Western diet and the sequential action of gut microbiota. Numerous studies reveal an association between systemic TMAO levels and cardiovascular risks in a variety of stable cohorts. The purpose of this study is to evaluate the efficacy of traditional Chinese Medicine formular (Compound pseudo-ginseng granules ) on the level of TMAO for the patient with acute coronary syndrome(ACS) undergoing percutaneous coronary intervention. 80 patients with ACS would be randomly allocated into interventional group(IG) and control group(CG). The patients in the IG would be administered by oral Compound pseudo-ginseng granules (twice per day ) for 90 days and those in the CG would receive the placebo twice per day during the same period. All of subjects would be administered with standard therapy in accordance with AHA/ACC guideline for ST-elevation myocardial infarction(STEMI) and Non ST-elevation myocardial infarction(NSTEMI).The primary endpoint is the plasma level of TMAO at 90-day follow-up. The second endpoint is the level of lipid, score of The Seattle Angina, fecal DNA extraction and pyrosequencing.

Studieoversigt

Status

Ukendt

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

80

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Kina
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510120
        • Rekruttering
        • Guangdong Provincial Hospital of Chinese Medicine
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. acute coronary syndrome (ACS), including ST segment elevate myocardial infarction(STEMI), Non-ST-segment elevation myocardial infarction(NSTEMI) and unstable angina(UA).
  2. TCM syndrome: Intermingled Phlegm and Blood Stasis.
  3. Aged 18 to 80 years old.
  4. sign a consent form.

Exclusion Criteria:

  1. Cardiogenic shock.
  2. Serious heart failure (NYHA IV or LVEF < 40%).
  3. With severe valvular heart disease.
  4. Severe hepatic or renal insufficiency, with serum Alanine aminotransferase ( ALT) 3 times higher than normal ceiling or serum creatinine not lower than 265 μmol/L.
  5. With acute cerebrovascular disease or severe mental illness.
  6. With active bleeding or severe hematopoietic system disease.
  7. With malignant tumor or life expectancy in less than three years.
  8. Pregnancy or ready to pregnant women, nursing mothers.
  9. History of taking antibiotics within the past two months.
  10. Participating in other clinical subjects .
  11. Failure to sign a consent form.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Compound Panax Notoginseng Granule
On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
Medicin: Compound Panax Notoginseng Granule

Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.

Frequency:two times a day, one package per time. Duration:three months.
Placebo komparator: Placebo Granule
On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
Medicin: Placebo Granule
Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
the plasma level of TMAO
Tidsramme: baseline
Trimethylamine-N-Oxide(μM) is relative to the prognostic of ACS.
baseline
the plasma level of TMAO
Tidsramme: 90-days post-procedure
Trimethylamine-N-Oxide(μM) is relative to the prognostic of ACS.
90-days post-procedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
metagenomic DNA sequencing analysis of faecal microbiome
Tidsramme: baseline
high-throughput sequencing and big data analytics
baseline
metagenomic DNA sequencing analysis of faecal microbiome
Tidsramme: 90-days post-procedure
high-throughput sequencing and big data analytics
90-days post-procedure
major adverse cardiac event
Tidsramme: 90-days post-procedure
frequency of the reported cardiovascular events (defined as death, non fatal myocardial infarction,target vessel revascularization and stent thrombosis )
90-days post-procedure
cardiac function
Tidsramme: baseline
left ventricular ejection fraction(LVEF) evaluated by echo
baseline
cardiac function
Tidsramme: 90-day at follow-up
left ventricular ejection fraction(LVEF) evaluated by echo
90-day at follow-up
Seattle Angina Questionnaire score
Tidsramme: 90-days
The Seattle Angina Questionnaire is a valid and reliable instrument that measures five clinically important dimensions of health in patients with coronary artery disease (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception).
90-days
The traditional Chinese medicine syndrome scale
Tidsramme: change from baseline at 90-days
The score of phlegm and of blood stasis syndromes is evaluated by Phlegm and blood stasis syndrome questionnaire.
change from baseline at 90-days
lipid metabolism
Tidsramme: change from baseline at 90-days
low-density lipoprote in cholesterol in mmol/L
change from baseline at 90-days
lipid metabolism
Tidsramme: change from baseline at 90-days
total cholesterol in cholesterol in mmol/L
change from baseline at 90-days
inflammatory factors
Tidsramme: change from baseline at 90-days
C-reactive protein in mg/L
change from baseline at 90-days
platelet function
Tidsramme: change from Baseline at 90-days
maximal aggregation rate of platelet in percent
change from Baseline at 90-days
cardiac biomarkers of necrosis
Tidsramme: Change from Baseline at 5 days
cardiac troponin T (cTnT) in ug/L
Change from Baseline at 5 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Guangdong Provincial Hospital of Traditional Chinese Medicine

Samarbejdspartnere

Beijing Genomics Institute

Efterforskere

  • Studieleder: Xiaoyan Li, Master, Guangdong Provincial Hospital of Traditional Chinese Medicine

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. december 2017

Primær færdiggørelse (Forventet)

31. maj 2018

Studieafslutning (Forventet)

31. august 2018

Datoer for studieregistrering

Først indsendt

7. juni 2017

Først indsendt, der opfyldte QC-kriterier

13. juni 2017

Først opslået (Faktiske)

14. juni 2017

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

7. december 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. december 2017

Sidst verificeret

1. december 2017

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • YN2015MS21

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Akut koronarsyndrom

Kliniske forsøg med Compound Panax Notoginseng Granule

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Ethiopia

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner